Chronic Steroids and Age Predict JAK Inhibitor Discontinuation in RA

This 8-year real-world registry helps rheumatology pharmacists risk-stratify JAK inhibitor candidates by identifying chronic glucocorticoid use and older age as distinct predictors of discontinuation for lack of effect versus adverse reactions.

tofacitinibbaricitinibupadacitinibfilgotinibJAK inhibitorsglucocorticoidsrheumatoid arthritisdrug retentionregistry studyreal-world evidenceolder adultsdiscontinuation Rheumatology / Immunology

Background Information

Glucocorticoids and age affect JAK inhibitor retention in RA.

Understanding factors affecting the effectiveness and safety of Janus kinase (JAK) inhibitors can improve treatment outcomes for rheumatoid arthritis (RA) patients. At 1 year, discontinuation rates were 23.0% for lack of effectiveness and 17.0% for adverse drug reactions (ADRs). Age and chronic concomitant glucocorticoid therapy significantly impacted these outcomes. Older RA patients and those on prolonged glucocorticoid therapy may have higher JAK inhibitor discontinuation rates; personalized treatment strategies might enhance efficacy and tolerance. Age and glucocorticoid use influence JAK inhibitor discontinuation rates in RA.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Martinez-Molina C, Frade-Sosa B, Diaz-Torné C, Sanmarti R, Corominas H

Citation: Martinez-Molina C, Frade-Sosa B, Diaz-Torné C, et al. Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry. RMD open. 2026;12(3). doi:10.1136/rmdopen-2026-007099

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →